94 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
platform under development. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.
IPH67 … will be responsible for all development, manufacturing and commercialization.
Sanofi still retains the option of one additional ANKET® target under the terms
6-K
EX-99.1
IPHA
Innate Pharma
15 Apr 24
Innate Pharma Announces Advancement Of Sanofi-Developed Nk Cell Engager Sar443579 / Iph6101 Progressing To Phase 2 For Blood Cancer Patients
6:02am
agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration
6-K
EX-99.1
ovoe6 81eos9o
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
6-K
EX-99.1
dequq x3orpl5
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
424B5
qt5 kiy6q
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
3e9 bhhoykp1umgbqjhg
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
EX-99.1
ohzyey
4 Jan 24
Innate Pharma 6-K
6:00am
UPLOAD
8mv ulzunffqmyiyve
26 Dec 23
Letter from SEC
12:00am
F-3
flfzgwq54
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-3.1
g50yk8hgk
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
EX-99.1
7meo5gb6v253v2n93e2p
20 Dec 23
Current report (foreign)
4:30pm
6-K
EX-99.1
j6c7jmmxtkqmy53
19 Dec 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
cos5cvmbqljuon1
11 Dec 23
Innate Pharma S.a. 6-K
6:00am